Ged Giblin
Corporate Officer/Principal presso Convergence Pharmaceuticals Ltd.
Profilo
Ged Giblin is currently the Head-Chemistry & Preclinical Development at Convergence Pharmaceuticals Ltd.
He previously worked as the Head-Medicinal Chemistry at GlaxoSmithKline (Pharmaceutical Operations).
Posizioni attive di Ged Giblin
| Società | Posizione | Inizio |
|---|---|---|
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | 06/10/2010 |
Precedenti posizioni note di Ged Giblin
| Società | Posizione | Fine |
|---|---|---|
| GlaxoSmithKline (Pharmaceutical Operations) | Corporate Officer/Principal | - |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
| GlaxoSmithKline (Pharmaceutical Operations) |
- Borsa valori
- Insiders
- Ged Giblin
